CorrGene
About:
CorrGene is a researcher and developer of rare disease cell therapy.
Top Investors: Wuxi Capital, Med-Fine Capital, Golden Capital Partners
Description:
CorrGene is an innovative company focusing on the research and development and production of new anti-cancer drugs and rare diseases with gene editing technology and cell therapy. The company was established by a group of cell and gene therapy experts, virologists, oncologists, hematologists and biopharmaceutical industry veterans. CorrGene was established in January, 2022 in Jiangsu, China.
Total Funding Amount:
$15.7M
Headquarters Location:
Nanjing, Jiangsu, China
Founded Date:
2022-01-01
Founders:
Number of Employees:
Last Funding Date:
2022-02-28
IPO Status:
Private
Industries:
© 2025 bioDAO.ai